A common mutation in the KRAS gene is associated with improved overall survival in pancreatic ductal adenocarcinoma (PDAC) compared with other variants, in part because the mutation appears to lead to ...

A research team led by Minyoung Lee and Sunggyu Park of The Korea Institute of Materials Science (KIMS) Bio & Health ...

Breakthrough research led by scientists in Manchester has identified a new drug combination that could improve outcomes for ...

Share on Pinterest New research shows certain KRAS mutations in pancreatic cancer may improve survival rates compared to other mutations. William Taufic/Getty Images In 2020, more than 495,000 adults ...

The pancreas is in the upper part of the abdomen. (Sebastian Kaulitzki/Science Photo Library/Getty Images) Pancreatic ductal ...

Mutations of KRAS have long been targets of interest for the development of new cancer therapies, but structural changes caused by these mutations have made it particularly difficult to target and ...

Colon cancer used to be treated the same way for almost everyone. That’s no longer true. Today, doctors are increasingly looking at the genetic makeup of each patient’s tumor to guide treatment ...

Dr. Marwan G. Fakih explains that KRAS mutations, found in 45% of patients with colorectal cancer, include the rare KRAS G12C mutation, leading to Lumakras approval. According to the National Cancer ...

July 6, 2012 — The US Food and Drug Administration (FDA) has approved the therascreen® KRAS RGQ PCR Kit to be sold as a companion diagnostic test for cetuximab (Erbitux). In addition, the FDA has ...

Spatial molecular profiling of a resected pancreatic adenocarcinoma. Fluorescently-labeled probes bind to RNA targets to identify the location of different cell types within a tumor sample. A common ...